HCW Biologics Inc.

HCWB

US40423R1059

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 03:00:23 2024-12-09 pm EST			5-day change	1st Jan Change
0.3930 ^USD	-1.97%		-23.51%	-68.16%

Nov. 19	HCW Biologics to Raise $6.9 Million in Gross Proceeds From Direct Offering, Private Placement; Shares Extend Gains Premarket	MT
Nov. 18	Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	MT

HCW Biologics Inc.(NasdaqGM:HCWB) added to S&P TMI Index

September 20, 2021 at 12:00 am EDT

Latest news about HCW Biologics Inc.

HCW Biologics to Raise $6.9 Million in Gross Proceeds From Direct Offering, Private Placement; Shares Extend Gains Premarket	Nov. 19	MT
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	Nov. 18	MT
Top Midday Gainers	Nov. 18	MT
HCW Biologics, WY Biotech Sign License Deal for Immunotherapeutic Product Candidate	Nov. 18	MT
HCW Biologics Inc. and Wy Biotech Announce License Agreement for Immunotherapeutic Product Candidate	Nov. 18	CI
Earnings Flash (HCWB) HCW BIOLOGICS Posts Q3 Revenue $426,423	Nov. 14	MT
HCW Biologics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	Nov. 14	CI
HCW Biologics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	Aug. 14	CI
HCW Biologics Inc. announced that it expects to receive $10 million in funding	May. 15	CI
HCW Biologics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 15	CI
HCW Biologics Inc. Enters into A Senior Secured Note Purchase Agreement with Purchasers	May. 01	CI
HCW Biologics Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Apr. 01	CI
HCW Biologics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Apr. 01	CI
HCW Biologics Inc. Auditor Raises 'Going Concern' Doubt	Mar. 31	CI
HCW Biologics Inc. announced that it has received $2.500005 million in funding	Feb. 19	CI
HCW Biologics Inc. Exercises Its Right to Terminate Its Credit Agreement	Jan. 12	CI
HCW Biologics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Earnings Flash (HCWB) HCW BIOLOGICS Reports Q3 Revenue $853,102	Nov. 14	MT
HCW Biologics Inc. Announces Results from Preliminary Human Data Readout from an Ongoing Phase 1 Clinical Trial Sponsored by the University of Minnesota	Nov. 08	CI
HCW Biologics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Earnings Flash (HCWB) HCW BIOLOGICS Reports Q2 Revenue $622,807	23-08-11	MT
Hcw Biologics Inc. Announces Appointment of Rick S. Greene as Class II Director	23-06-14	CI
HCW Biologics Says It Received Patent for Methods to Treat Diseases Caused by Chronic Inflammation	23-06-14	MT
EF Hutton Assumes HCW Biologics at Buy With $9 Price Target	23-06-01	MT
HCW Biologics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09	CI

HCW Biologics Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases, such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, autoimmune diseases, as well as other conditions such as long-haul COVID-19. It has developed a Tissue factOr-Based fusion (TOBI) discovery platform to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties. Its lead product candidates include HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth factor-Î² and stimulate immune cells, targeting senescent cells and the SASP factors they secrete. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes. Its other product candidates include HCW9201, HCW9206, and others.

Employees

Sector

Biotechnology & Medical Research

Calendar

2025-03-31 - Q4 2024 Earnings Release (Projected)

More about the company